INTRODUCTION
============

Numerous studies have suggested that exposure to magnetic fields affects various physiological and pathological processes. For instance, magnetic fields have been considered as a \"possible risk factor\" for childhood leukemia, brain tumor or breast cancer ([@B12]; [@B14]; [@B49]; [@B24]). On the other hand, therapeutic intervention with repetitive transcranial magnetic stimulation has shown to be beneficial for improving symptoms of Parkinson\'s disease ([@B15]; [@B11]) or several psychiatric diseases ([@B16]; [@B37]).

The activator protein-1 (AP-1) transcription factors are composed of Fos and Jun proteins in a Fos/Jun heterodimeric or Jun/Jun homodimeric complex that recognize and bind to specific DNA sequences (5\'-TGAGTCA-3\') in the promoter regions of a number of genes ([@B35]; [@B23]). Temporal expression profiles of each member of the Fos family, including c-Fos ([@B50]; [@B38]; [@B19]), FosB ([@B7]; [@B10]; [@B2]), ΔFosB ([@B7]; [@B10]) and fos-related antigen (FRA) ([@B50]; [@B38]; [@B2] and [@B3]; [@B36]; [@B19]) have been characterized in various *in vivo* animal models. In particular, a 35-kDa FRA have shown long-lasting expression pattern in response to chronic drug treatment or chronic neuronal stimulation ([@B38]; [@B2] and [@B3]; [@B19]), suggesting that prolonged induction of 35-kDa FRA is important for regulating genes related to neuronal adaptation ([@B35]; [@B34]; [@B13]; [@B3]). We also have demonstrated the induction of 35-kDa FRA after treatment with kainic acid ([@B26]; [@B27]), cocaine ([@B22]; [@B25]), or methamphetamine ([@B41]).

Magnetic fields have shown to affect behavioral profiles regulated by dopaminergic system ([@B47]; [@B8]; [@B42]; [@B20]; [@B40]; [@B30]) in rodents. In the previous study, we demonstrated that exposure to extremely low frequency magnetic fields (ELF-MF) increases striatal dopamine levels ([@B28]), and that ELF-MF induces hyperlocomotor activity via dopaminergic D1 receptor stimulation ([@B40]).

Little is known about the role of magnetic fields in modulations of AP-1 transcription factors *in vivo*, although magnetic fields-induced up-regulations in AP-1 transcription factors have demonstrated *in vitro* ([@B29]; [@B17]). Since FRA is the most important factor of the AP-1 modulation of genes necessary for neuronal adaptation ([@B34]; [@B1]; [@B2]), we examined FRA-immunoreactivity (FRA-IR) in the striatum and nucleus accumbens (striatal complex) after ELF-MF exposure, and we evaluated whether dopaminergic receptors are involved in the induction of FRA by applying dopaminergic D1 receptor antagonist, SCH 233390 and dopaminergic D2 receptor antagonist, sulpiride. Unexpectedly, we observed that FRA-IR lasted for at least 1 year after final exposure to ELF-MF. This long-lasting FRA-IR requires activation of dopaminergic D1 receptor.

MATERIALS AND METHODS
=====================

Animals and treatments
----------------------

All mice were handled in accordance with the US National Institute of Health guidelines for the humane care of laboratory animals and the Institutional Animal Care and Use Committee of Kangwon National University. Male adult C57BL/6 mice (Orient Bio Inc., Charles River Technology, Gapyung-Gun, Gyeonggi-Do, Korea), weighing 25±2 g, were maintained on a 12:12 h light:dark cycle, with food and water available *ad libitum*. The ambient conditions were maintained at 20±2℃. Mice were adapted to these conditions for 2 weeks before the experiments.

The ELF-MF was generated with three Helmholtz coils, set parallel to each other, in a wooden frame ([@B28]; [@B40]). The ELF-MF consisted of 60-Hz time-varying fields and the magnetic flux density was 0.3 or 2.4 mT. Animals were exposed to ELF-MF for 1 h/day for fourteen days. As seven days\' exposure to ELF-MF was not fully enough for locomotor stimulation ([@B40]), we extended exposure period by fourteen days in this study. Thirty minutes before the animals were exposed to ELF-MF, mice were treated with SCH23390 hydrochloride (SCH, D1 antagonist; Tocris Co., Ellisville, MO, USA) at 0.03 or 0.1 mg/kg, i.p. or (RS)-(±) sulpiride (Sulp, D2 antagonist; Tocris Co.) at 10 or 20 mg/kg, i.p. ([@B40]). Locomotor activity was measured 0 hour, 1 day, 1 week, 3 months or 1 year after the final ELF-MF exposure using an automated video-tracking system (Noldus Information Technology, Wagenin, The Netherlands). Eight test boxes (40×40×30 cm high) were operated simultaneously by a computer. Animals were studied individually during locomotion in the test box. A printout for each session showed the pattern of ambulatory movements in the test box. The distance traveled (in cm) was analyzed for 30 min. Data were collected and analyzed between 9:00 and 17:00 h. Animals were sacrificed for immunohistochemical analyses 90 min after measurement of locomotor activity.

Immunohistochemistry
--------------------

Sections containing the nucleus accumbens and striatum were processed for FRA immunohistochemistry. Prior to incubation with the primary antibody, sections were preincubated in PBS containing 0.2% Triton X-100 and 4% normal goat serum for 20 min. After 48-h incubation with the primary antibody against FRA (1 : 2,000, [@B50]; [@B1]; [@B25]) at 4℃, sections were incubated with the secondary biotinylated anti-rabbit IgG (1 : 1,000; Vector Laboratories, Inc., Burlingame, CA, USA) for 1 h, and immersed in avidin-biotinperoxidase complex (ABC Kits; Vector Laboratories, Inc.) for 1 h. 3,3\'-Diaminobenzidine was used as the chromogen. Digital images of FRA-immunoreactive neurons were acquired on an Olympus microscope (Tokyo, Japan), using an attached digital microscope camera (Olympus, Tokyo, Japan) and a personal computer. A region of interest (ROI), having an area of 0.1 mm^2^, was created using Optimas (version 6.51; Media Cybernetics, Inc., Silver Spring, MD, USA). Cell counting was performed blindly by two investigators and their results were averaged. Results are indicated as the number of FRA-immunoreactive cells /0.1 mm^2^.

Statistics
----------

Data were analyzed using analysis of variance (ANOVA) and *Post-hoc* Fisher\'s PLSD test was followed for the comparison among groups. A p value less than 0.05 was deemed to be statistically significant.

RESULTS
=======

Experimental schedules are shown in [Fig. 1](#F1){ref-type="fig"}. Control mice showed a basal locomotor activity ([Fig. 2](#F2){ref-type="fig"}). Locomotor activity was significantly increased immediately after the final exposure to ELF-MF in a field intensity-dependent manner, and it remains elevated 1 week later (0 hour and 1 day: Saline+0.3 or 2.4 mT vs. Saline+Control, p\<0.05 or p\<0.01; 1 week: Saline+2.4 mT vs. Saline+Control, p\<0.05). However, locomotor activity returned near control level 3 months after the final exposure to ELF-MF. ELF-MF-induced hyperlocomotor activity was significantly attenuated by treatment with SCH23390, a dopaminergic D1 receptor antagonist in a dose-related manner \[0 hour: SCH23390 (0.1 mg/kg)+2.4 mT vs. Saline+2.4 mT, p\<0.01; 1 day: SCH23390 (0.03 or 0.1 mg/kg)+2.4 mT vs. Saline+2.4 mT, p\<0.05 or p\<0.01; 1 week: SCH23390 (0.1 mg/kg)+2.4 mT vs. Saline+2.4 mT, p\<0.05\]. However, dopaminergic D2 receptor antagonist, sulpiride did not significantly alter hyperlocomotor activity induced by ELF-MF ([Fig. 2](#F2){ref-type="fig"}).

FRA-immunoreactive cells were barely observed in the striatal complex of the control ([Fig. 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}). Repeated exposure to ELF-MF significantly increased FRA-IR in the striatal complex 2 hours after the final exposure in a field intensity-dependent manner, and this FRA induction lasted for 1 year (both of striatum and nucleus accumbens at 2 hours, 1 day, 1week, 3 months and 1 year: Saline+0.3 or 2.4 mT vs. Saline+Control, p\<0.01). Treatment with SCH23390 (0.1 mg/kg, i.p.) significantly attenuated the ELF-MF-induced increase in FRA-IR in the striatum \[0 hour, 1 day and 1week: SCH23390+2.4 mT vs. Saline+2.4 mT, p\<0.01; 3 months and 1 year: SCH23390+2.4 mT vs. Saline+2.4 mT, p\<0.05\] and nucleus accumbens \[0 hour, 1 day, 1week and 3 months: SCH23390+2.4 mT vs. Saline+2.4 mT, p\<0.01; 1 year: SCH23390+2.4 mT vs. Saline+2.4 mT, p\<0.05\], while sulpiride (20 mg/kg, i.p.) did not significantly affect FRA-IR induced by ELF-MF ([Fig. 3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}).

DISCUSSION
==========

To our knowledge, this is the first demonstration that repeated exposure to ELF-MF produces nearly permanent induction of FRA in the striatal complex *in vivo*. Elevated FRA-IR lasted for at least 1 year after final exposure to ELF-MF in the present study. A number of studies have suggested that transient and short-term expression of FRA proteins is a marker of extracellular stimuli ([@B33]; [@B2]; [@B9]), while long-term expression of FRA mediates neuronal adaptation through the persistent activation of the AP-1 binding site in the nucleus ([@B1] and [@B2]; [@B36]). AP-1 binding sites are located in the promoter regions of various genes, including tyrosine hydroxylase, proenkephalin, prodynorphin, and glial fibrillary acidic protein ([@B35]; [@B32]). Among these genes, proenkephalin- and prodynorphin-gene expressions have shown temporal correlation with long-lasting expressions of 35-kDa FRA induced by psychostimulants ([@B5]; [@B41]) or kainate ([@B3]; [@B27]). Enkephalin and dynorphin, which are derived from proenkephalin precursor and prodynorphin precursor, respectively, have been suggested to play an important role in the neuroadaptive responses related to behavioral sensitization, drug reward, drug withdrawal, or recovery of motor function via modulating post-synaptic dopaminergic receptor sensitivity or pre-synaptic dopamine release ([@B43]; [@B6]). Moreover, it has been reported that exposure to magnetic fields increases prodynorphin gene expression ([@B46]) and regulates the activity of opioid receptors ([@B44]). Therefore, it may be possible that proenkephalin- and prodynorphin-genes may be involved in the neuroadaptive responses mediated by long-term FRA expression in response to ELF-MF, although the role and physiological significance of the long-term expression of FRA induced by ELF-MF remain to be further clarified.

In the present study, ELF-MF-induced long-lasting FRA expression in the striatal complex was attenuated by SCH23390, a dopaminergic D1 antagonist, but not by sulpiride, a dopaminergic D2 antagonist, suggesting that ELF-MF induces long-lasting FRA-IR via stimulation of dopaminergic D1 receptor. These results are in line with previous findings showing that direct stimulation of D1 receptor with specific agonist ([@B48]) or indirect stimulation of D1 receptor with psychostimulants ([@B50]; [@B5]; [@B51]) augments FRA expression in the striatal complex. Especially, it has been suggested that dopaminergic D1 receptor-mediated adenylate cyclase signaling pathway, but not phospholipace C pathway, is necessary for inducing FRA in the striatum ([@B48]). Although it is not clear how ELF-MF stimulates dopaminergic D1 receptor, it has been reported that ELF-MF exposure alters intracellular Ca^2+^ levels and facilitates releases of neurotransmitters ([@B4]; [@B39]). Thus, there is a possibility that ELF-MF might increase dopamine release into the synaptic cleft through the modulation of Ca^2+^ influxes. In addition, elevation in dopamine level in the striatum after repeated exposure to ELF-MF has reported ([@B28]; [@B42]). However, Janać et al. ([@B21]) indicated that ELF-MF does not change the affinity and density of striatal dopaminergic receptor. In their study ([@B21]), rats were fully exposed to ELF-MF for up to 7 days, whereas mice were exposed to ELF-MF for consecutive 14 days in our present study. Since it has been suggested that ELF-MF-induced change in neuronal activity and behaviors may be affected by exposing schedule ([@B31]), it requires further study to achieve better understanding on the discrepancy between Janać et al. ([@B21]) and current finding.

In the behavioral evaluation, locomotor activity was increased after repeated exposure to ELF-MF, and it returned near control level 3 months later. ELF-MF-induced hyperlocomotor activity was also attenuated by dopaminergic D1 antagonist, SCH23390. Although locomotor activity can not fully support time-dependent pattern in FRA in the striatal complex, we raise the possibility that FRA expression modulates, at least in part, behavioral responses to repeated ELF-MF exposure. It has been reported that induction of 35-kDa FRA is accompanied with behavioral changes during repeated treatment with psychostimulants, such as cocaine ([@B38]; [@B18]) or amphetamine ([@B45]). Striatal expression of 35-kDa FRA and hyperlocomotor activity after repeated treatment with cocaine or amphetamine have shown to be more pronounced than those after single injection ([@B18]; [@B45]), suggesting that 35-kDa FRA plays a key role in repeated neuronal stimulation. In addition, Hsieh et al. ([@B19]) reported that elevated 35-kDa FRA expression, but not c-Fos expression, is sustained for at least 40 days after withdrawal from repeated amphetamine administration, while locomotor activity returned near control level 10 days after withdrawal, suggesting that 35-kDa FRA plays a certain role in neurobehavioral adaptation.

Our results suggest that repeated exposure to ELF-MF induces prolonged locomotor stimulation and long-term expression of FRA in the striatal complex via stimulation of dopaminergic D1 receptor. Finally, we raise the possibility that ELF-MF-mediated dopaminergic activations can be one of the therapeutic interventions for improving Parkinson\'s symptoms.
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![Experimental schedule for evaluating effects of repeated exposure to extremely low frequency magnetic fields (ELF-MF) on the locomotor activity and fos-related antigen-immunoreactivity (FRA-IR) in the striatum and nucleus accumbens (striatal complex) of the mice. Animals were exposed to ELF-MF (0.3 or 2.4 mT, 1 hour/day) for consecutive 14 days. Thirty minutes before each exposure to ELF-MF, mice were treated with SCH23390 hydrochloride (a dopaminergic D1 antagonist; 0.03 or 0.1 mg/kg, i.p.) or sulpiride (a dopaminergic D2 antagonist; 10 or 20 mg/kg, i.p.). Locomotor activity was measured 0 hour, 1 day, 1 week, 3 months and 1 year after the final ELF-MF exposure using an automated video-tracking system. Mice were sacrificed for immunocytochemical evaluation 90 min after the measurement of locomotor activity. ^\*^SCH23390 (a dopaminergic D1 antagonist; 0.03 or 0.1 mg/kg, i.p.) or Sulpiride (a dopaminergic D2 antagonist; 10 or 20 mg/kg, i.p.) was injected 30 min prior to ELF-MF exposure. ^§^Behavioral evaluation followed by immunocytochemical study.](en-20-130-g001){#F1}

![Changes in locomotor activity after repeated exposure to extremely low frequency magnetic fields (ELF-MF) in the mice. Locomotor activity was measured 0 hour, 1 day, 1 week, 3 months and 1 year after the final ELF-MF exposure. SCH 0.03 or 0.1=SCH 23390 at 0.03 or 0.1 mg/kg, i.p. Sulp 10 or 20=sulpiride at 10 or 20 mg/kg, i.p. Each value is the mean±S.E.M. of 6 mice. ^\*^p\<0.05, ^\*\*^p\<0.01 vs. Saline+Control, ^&^p\<0.05 vs. Saline+0.3 mT ELF-MF, ^\#^p\<0.05, ^\#\#^p\<0.01 vs. Saline+2.4 mT ELF-MF (One-way ANOVA followed by Fischer\'s PLSD test).](en-20-130-g002){#F2}

![Changes in fos-related antigen-immunoreactivity (FRA-IR) after repeated exposure to extremely low frequency magnetic fields (ELF-MF) in the striatum of the mice. SCH 0.1=SCH 23390 at 0.1 mg/kg, i.p. Sulp 20=sulpiride at 20 mg/kg, i.p. Each value is the mean±S.E.M. of 6 mice. ^\*^p\<0.01 vs. Saline+Control, ^&^p\<0.05, ^&&^p\<0.01 vs. Saline+0.3 mT ELF-MF, ^\#^p\<0.05, ^\#\#^p\<0.01 vs. Saline+2.4 mT ELF-MF (One-way ANOVA followed by Fischer\'s PLSD test).](en-20-130-g003){#F3}

![Changes in fos-related antigen-immunoreactivity (FRA-IR) after repeated exposure to extremely low frequency magnetic fields (ELF-MF) in the nucleus accumbens of the mice. SCH 0.1=SCH 23390 at 0.1 mg/kg, i.p. Sulp 20=sulpiride at 20 mg/kg, i.p. Each value is the mean±S.E.M. of 6 mice. ^\*^p\<0.01 vs. Saline+Control, ^&^p\<0.05, ^&&^p\<0.01 vs. Saline+0.3 mT ELF-MF, ^\#^p\<0.01 vs. Saline+2.4 mT ELF-MF (One-way ANOVA followed by Fischer\'s PLSD test).](en-20-130-g004){#F4}
